General MedicationsINTRATRACHEALStandard
CUROSURF
PORACTANT ALFA
Standard Dose
80MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview CUROSURF is listed in Drugs@FDA under application 020744 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient PORACTANT ALFA Form and strength SUSPENSION;INTRATRACHEAL - 80MG/ML Sponsor CHIESI USA INC Submission history Latest submission status date: 2021-05-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview CUROSURF is listed in Drugs@FDA under application 020744 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient PORACTANT ALFA Form and strength SUSPENSION;INTRATRACHEAL - 80MG/ML Sponsor CHIESI USA INC Submission history Latest submission status date: 2021-05-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.